Which atypical antipsychotic is known to decrease the suicide rate in psychotic patients?

Clozapine is recognized for its unique efficacy in reducing the risk of suicide among patients with psychotic disorders, particularly treatment-resistant schizophrenia. This atypical antipsychotic not only effectively manages psychotic symptoms but also has specific anti-suicidal properties that have been supported by substantial clinical research.

Clozapine is particularly distinct among antipsychotics due to its action on various neurotransmitter systems and its ability to improve overall mood and emotional regulation. The reduction in suicidal ideation is a critical aspect of its therapeutic profile, making it exceptional compared to other options.

While other atypical antipsychotics may be effective in managing psychotic symptoms, they do not have the same level of evidence supporting a significant reduction in suicide risk. This is a key consideration in the treatment of patients with severe mental illness, where suicidality is a serious concern.